Xavier T. Reveles Publications

 

 

Xavier T. Reveles Publications

Molecular cytogenetics as a clinical test for prognostic and predictive biomarkers in newly diagnosed ovarian cancer.

Gunn S, Reveles X, Weldon K, Barrera A, Ishaque M, Taylor D, McCaskill C, Kim J, Shah R, Mohammed M, Barry T, Kaiser B, Patnaik A, Tolcher A.

J Ovarian Res. 2013 Jan 4;6(1):2. doi: 10.1186/1757-2215-6-2.

 

PHC3, a component of the hPRC-H complex, associates with E2F6 during G0 and is lost in osteosarcoma tumors.

Deshpande AM, Akunowicz JD, Reveles XT, Patel BB, Saria EA, Gorlick RG, Naylor SL, Leach RJ, Hansen MF.

Oncogene. 2007 Mar 15;26(12):1714-22. Epub 2006 Sep 25.

 

Detection of recurrent copy number loss at Yp11.2 involving TSPY gene cluster in prostate cancer using array-based comparative genomic hybridization.

Vijayakumar S, Hall DC, Reveles XT, Troyer DA, Thompson IM, Garcia D, Xiang R, Leach RJ, Johnson-Pais TL, Naylor SL.

Cancer Res. 2006 Apr 15;66(8):4055-64.

 

Use of DNA sequencing analysis to confirm fungemia due to Trichosporon dermatis in a pediatric patient.

Gunn SR, Reveles XT, Hamlington JD, Sadkowski LC, Johnson-Pais TL, Jorgensen JH.

J Clin Microbiol. 2006 Mar;44(3):1175-7.

 

Golli-MBP copy number analysis by FISH, QMPSF and MAPH in 195 patients with hypomyelinating leukodystrophies.

Vaurs-Barriere C, Bonnet-Dupeyron MN, Combes P, Gauthier-Barichard F, Reveles XT, Schiffmann R, Bertini E, Rodriguez D, Vago P, Armour JA, Saugier-Veber P, Frebourg T, Leach RJ, Boespflug-Tanguy O.

Ann Hum Genet. 2006 Jan;70(Pt 1):66-77.

 

Chromosome 18 suppresses prostate cancer metastases.

Padalecki SS, Weldon KS, Reveles XT, Buller CL, Grubbs B, Cui Y, Yin JJ, Hall DC, Hummer BT, Weissman BE, Dallas M, Guise TA, Leach RJ, Johnson-Pais TL.

Urol Oncol. 2003 Sep-Oct;21(5):366-73.

 

Molecular characterization of a patient with central nervous system dysmyelination and cryptic unbalanced translocation between chromosomes 4q and 18q.

Gunn SR, Mohammed M, Reveles XT, Viskochil DH, Palumbos JC, Johnson-Pais TL, Hale DE, Lancaster JL, Hardies LJ, Boespflug-Tanguy O, Cody JD, Leach RJ.

Am J Med Genet A. 2003 Jul 1;120A(1):127-35.

 

Regions of allelic imbalance in the distal portion of chromosome 12q in gastric cancer.

Schneider BG, Rha SY, Chung HC, Bravo JC, Mera R, Torres JC, Plaisance KT Jr, Schlegel R, McBride CM, Reveles XT, Leach RJ.

Mol Pathol. 2003 Jun;56(3):141-9.

 

Molecular characterization of 18p deletions: evidence for a breakpoint cluster.

Schaub RL, Reveles XT, Baillargeon J, Leach RJ, Cody JD.

Genet Med. 2002 Jan-Feb;4(1):15-9.

 

Genetic mapping of a novel X-linked recessive colobomatous microphthalmia.

Lehman DM, Sponsel WE, Stratton RF, Mensah J, Macdonald JC, Johnson-Pais TL, Coon H, Reveles XT, Cody JD, Leach RJ.

Am J Med Genet. 2001 Jun 15;101(2):114-9.

 

Haplosufficiency of the melancortin-4 receptor gene in individuals with deletions of 18q.

Cody JD, Reveles XT, Hale DE, Lehman D, Coon H, Leach RJ.

Hum Genet. 1999 Nov;105(5):424-7.

 

Assignment of serine protease 17 (PRSS17) to human chromosome bands 19q13.3–>q13.4 by in situ hybridization.

DuPont BR, Hu CC, Reveles X, Simmer JP.

Cytogenet Cell Genet. 1999;86(3-4):212-3. No abstract available.

 

 

“Meso-tetra (4-carboMeso-tetra (4-carboxyphenyl) porphyrin (TCPP) is taken up in cancer cells by the CD320 receptor” at the International Conference on Porphyrins and Phthalocyanines (ICPP) ICPP-11, June 26 through July 2, 2021

The poster presents the novel mechanism by which the porphyrin TCPP, which is used in bioAffinity Technologies’ non-invasive test for the early detection of lung cancer, is incorporated into cancer cells. These discoveries have furthered our understanding of TCPP for use in diagnostics including the Company’s first product, CyPath® Lung, a flow cytometry test used to diagnose lung cancer at early stage.

read more

“Selective Cancer Cell Killing by Dual siRNA Knockdown of CD320 and LRP2 Receptors” RNA Therapeutics Institute’s 2021 RNA Therapeutics Symposium at the University of Massachusetts Medical School June 23 – 25, 2021

The presentation explains bioAffinity Technologies’ discovery of a fundamental vulnerability of cancer opens the way to new therapies that kill cancer without harm to normal tissue. In particular, bioAffinity’s research shows how the Company has designed and used siRNAs to kill multiple cancers at the cellular level including prostate, lung, breast, brain and skin cancers without harm to normal cells.

read more

“Simultaneous knockdown of CD320 and LRP2 receptors is selectively toxic to cancer cells but not normal cells,” American Association of Cancer Research (AACR) Annual Meeting 2021, April-May, 2021

The presentation reports on research leading to selective killing of cancer cells without harm to normal cells. During efforts to elucidate the mechanism by which TCPP selectively accumulates in cancer cells, we discovered that simultaneous knock down of two LDLR-family receptors was selectively cytotoxic to cancer cells and not to normal cells.

read more